Retinal Vein Occlusion (RVO)

The Company intends to conclude phase II studies on its own in the prioritized indication RVO, in order to increase the possibility that an agreement of partnership, licensing or sale can be reached with favorable terms for the Company.

RVO is a disease of the eye and one of the most common causes of vision loss worldwide, affecting over 16 million people globally with approximately 500,000 RVO patients in the United States and about 1.2 million RVO patients in Europe. RVO can be further grouped into “Branch Retinal Vein Occlusion (BRVO)” (about 14 million patients in the world) and “Central Retinal Vein Occlusion (CRVO)” (approximately 2.5 million patients worldwide).

As far as the Company is aware, ANXV is the only product under development that can remove the blockage in the vein that causes RVO and which can also offer a new mechanism of action. At present there are no drugs that treat the cause of RVO. Only complications from RVO are treated with so-called anti-VEGF agents for the purpose of preventing growth of new interfering blood vessels in the retina, or corticosteroids against inflammation, injected or implanted directly into the eye. The cost of an anti-VEGF injection amounts to approximately SEK 9,000. It is also being tested for laser treatment, for example. These treatments have increased the chances of visual improvement. Neither, however, has shown positive effects in the acute situation. The RVO market is projected to increase by 11.2% per annum to 2023 and valued at $7 billion by 2016.